A Cannabinoid Agonist Raised Insulin Sensitivity and a CB1 Blocker Lowered It: Inside an NIH Clamp Study
A National Institute on Aging crossover study used sequential glucose clamps in 21 healthy men to test whether the endocannabinoid system insulin sensitivity link holds up under direct measurement. The cannabinoid agonist nabilone significantly raised…
Clinical Evidence of Tirzepatide’s Cardiometabolic Benefits in Obesity
Tirzepatide cardiometabolic benefits extend beyond weight loss in obese non-diabetic adults. Clinical trials demonstrate improvements in blood pressure, lipid profiles, and inflammation. This evidence supports tirzepatide as a metabolic intervention…
Cannabinoids & Insulin Sensitivity
CED Clinical Relevance #62 Moderate Clinical Relevance Useful mechanistic human data, but not evidence that cannabis improves metabolism in everyday life. Clinical Insight | CED Clinic This cannabinoid insulin sensitivity study shows that cannabinoid…
How Cannabinoid Signaling Shapes Insulin Sensitivity in Humans
Cannabinoid receptor insulin sensitivity is explored in a controlled human trial using gold-standard metabolic clamp techniques. The findings show that CB1 receptor activity can shift insulin sensitivity without altering insulin secretion. This study…
GLP-1 Cardiovascular Outcomes: Metabolic Health Phenotypes
Metabolic health phenotypes influence cardiovascular outcomes beyond BMI alone. Understanding these phenotypes helps tailor GLP-1 therapy for better cardiometabolic risk management. This approach supports personalized treatment for patients with obesity…